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Cardiovascular diseases are associated to risk factors as obesity, hypertension and diabetes. The 
transforming growth factor-β1 receptors ALK1 and endoglin regulate blood pressure and vascular 
homeostasis. However, no studies relate the association of ALK1 and endoglin polymorphisms with 
cardiovascular risk factors. We analysed the predictive value of the ALK1 and endoglin polymorphisms 
on cardiovascular target organ damage in hypertensive and diabetic patients in 379 subjects with or 
without hypertension and diabetes in a Primary Care setting. The ALK1 rs2071219 polymorphism (AA 
genotype) is associated with a lower presence of diabetic retinopathy and with the absence of altered 
basal glycaemia. Being carrier of the ALK1 rs3847859 polymorphism (G allele) is associated with 
lower basal heart rate and with higher LDL-cholesterol levels. The endoglin rs3739817 polymorphism 
(AA genotype) is associated with higher levels of LDL-cholesterol, and being carrier of the endoglin 
rs10987759 polymorphism (C allele) is associated with higher haemoglobin levels and with an increased 
heart rate. Summarizing, several ALK1 and endoglin gene polymorphisms increase the risk of 
cardiovascular events. The analysis of these polymorphisms in populations at risk, in combination with 
the determination of other parameters and biomarkers, could implement the diagnosis and prognosis 
of susceptibility to cardiovascular damage.
Cardiovascular diseases are the main cause of death worldwide1, which are associated to common risk factors as 
obesity, hypertension (HT) and diabetes mellitus (DM)2,3. HT is the origin of cardiovascular complications such 
as peripheral arterial disease, ictus and heart attack. Cardiovascular risk increases markedly with high blood pres-
sure (BP), DM and other risk factors2, including renal4, cardiac5 and vascular target organ damage6,7. Both large 
and small vessels may be affected in these syndromes. Atherosclerosis damages large vessels, whereas in disorders 
such as retinopathy, small vessels become altered. For instance, several studies have described the association of 
retinal vessel caliber with left ventricular hypertrophy (LVH)8, arterial HT9, metabolic syndrome10, cerebrovas-
cular accident11, coronary diseases12 and cardiovascular risk.
Transforming growth factor-β1 (TGF-β1) participates in BP regulation and vascular homeostasis13. In recent 
years, our research group has studied the effect of several TGF-β1 receptors, such as ALK1 and endoglin, on car-
diovascular and renal regulation. Endoglin (CD150, TGF III receptor) is involved in angiogenesis, and its role in 
cardiovascular risk is well documented14, as increased plasma levels of soluble endoglin are involved in coronary 
vasoconstriction, which may cause myocardial ischemia15, cardiac fibrosis and peripartum cardiomyopathy16. 
We have described how soluble endoglin levels are related with glycaemia, systolic BP, pulse pressure and pres-
ence of LVH17, and that endoglin is involved in endothelial regulation through cyclooxygenase-2 expression and 
activity18 and nitric oxide-dependent vasodilation19. Moreover, hypercholesterolemia, coronary heart disease, 
DM and HT contribute to increase serum endoglin levels20. Endoglin is also upregulated in experimental models 
of renal fibrosis21. On the other hand, ALK1 expression is self-regulated during periods of active angiogenesis22. 
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Our group has also verified the regulatory role of ALK1 in arterial pressure and in cardiovascular physiopa-
thology23 and in the development of renal fibrosis24.Despite the existence of these studies that relate ALK1 and 
endoglin receptors to vascular and renal pathophysiology and cardiovascular risk, at present there are no studies 
linking the presence of polymorphic variants in these genes with different cardiovascular risk factors. Therefore, 
we selected four polymorphisms of these two genes, ALK1 rs2071219 and rs3847859, and endoglin rs3739817 
and rs10987759, all of them associated with vascular alterations (pulmonary hypertension, arteriovenous mal-
formations), with high prevalence in the general population and whose presence apparently does not influence 
the biological activity of the protein, and we analyse the association and predictive value of these polymorphic 
variants on cardiovascular target organ damage in at-risk populations (HT and DM patients).
Results
We included 379 subjects in the study. The distribution of genotypes of ALK1 rs2071219 and rs3847859 and 
endoglin rs3739817 and rs10987759 polymorphisms in control samples are in Hardy-Weinberg equilibrium 
(Table 1). Their demographic, clinical and physical variables are shown in Tables 2 and 3.
The ALK1 rs2071219 polymorphism is related to the presence of early signs of diabetic retinopathy, as the 
presence of the AA genotype is associated with a higher mean AVIx, which would imply a lower presence of 
retinopathy in hypertensive and diabetic patients (Table 4). Moreover, being carrier of the A allele is associated 
with the absence of altered basal glycaemia (Table 4). Regarding the other polymorphism, there are significant dif-
ferences in the ALK1 rs3847859 genotypic distribution between patients with basal heart rate <70 bmp (n = 219) 
or >70 bmp (n = 170). Being carrier of the G allele is associated with a lower basal heart rate in the recessive 
model (Tables 5 and 6). In addition, being carrier of the G allele is associated with higher LDL-cholesterol levels 
(Table 6).
The presence of the AA genotype in the endoglin rs3739817 polymorphism is associated with higher levels of 
LDL-cholesterol, as being carrier of the A allele is associated with higher levels of LDL-cholesterol in the domi-
nant model (p = 0.055) (Table 7). Besides, being carrier of the C allele in the endoglin rs10987759 polymorphism 
Gene SNP ID Base change SNP Chr location Assay ID HWE
ALK1 rs2071219 g.51913524 A > G intron variant 12:51913524 C_15868502_10 >0,05
ALK1 rs3847859 g.51899716 G > A intergenic 12:51899716 C_3240243_10 >0,05
ENG rs3739817 c.1029 G > A p.Thr343= 9:127824409 C_27491008_10 >0,05
ENG rs10987759 g.127856098 T > C utv 9:127856098 C_31370278_20 >0,05
Table 1. Characteristics of the ALK1 and endoglin polymorphisms. Chr: chromosome; HWE: Hardy Weinberg 




Diabetes mellitus 88 23.2
Target organ damage 175 46.2
Altered basal glycaemia 45 11.9
BMI <25 67 17.7
BMI 25-30 197 52.0
BMI >30 115 30.3
Dyslipidaemia 259 68.3
Elevated PP 92 24.3
LVH 69 18.2
C-IMT 67 17.7
Altered PWV 58 15.3
PAD 6 1.6
CV risk <1% 53 14.0
CV risk 1–5% 181 47.8
CV risk 5–10% 78 20.6
CV risk >10% 67 17.7
Antihypertensive drugs 210 55.4
Antidiabetic drugs 61 16.1
Lipid-lowering drugs 149 39.3
Table 2. Characteristics of the 379 patients included in the study. BMI: body mass index; C-IMT: carotid intima 
media thickness; CV: cardiovascular; HT: hypertension; LVH: left ventricular hypertrophy; PAD: peripheral 
arterial disease; PP: pulse pressure; PWV: pulse wave velocity.
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is associated with higher haemoglobin levels in the dominant model (Table 8). In addition, being carrier of the C 
allele is associated with an increased heart rate also in the dominant model (Table 8).
Discussion
The relationship between different cardiovascular alterations and the presence of polymorphic variants in numer-
ous genes has been documented extensively in recent years. Many of these studies have been conducted in pop-
ulations of a specific ethnic origin, so their relevance has a local or geographical character, depending on the 
size and characteristics of the population included in the study. Several studies analyze the association of gene 
polymorphisms with cardiovascular disease in the Caucasian population25–27. These and many other studies show 
that the presence of polymorphic variants in numerous genes involved in cardiovascular regulation may favor the 
risk or predisposition to a broad spectrum of cardiovascular disorders.
N Average ± SD
Male Female
P valueN Average ± SD N Average ± SD
Weight. Kg 379 76.53 ± 14.70 201 82.95 ± 13.48 178 69.27 ± 12.51 > 0.05
Age. years 379 60.29 ± 9.70 201 59.35 ± 10.27 178 61.36 ± 8.93 > 0.05
BMI. Kg/m2 379 28.61 ± 4.42 201 28.91 ± 3.83 178 28.28 ± 4.99 > 0.05
SBP. mmHg 379 133.89 ± 17.19 201 136.62 ± 16.96 178 130.81 ± 16.97 > 0.05
DBP. mmHg 379 81.16 ± 10.56 201 82.76 ± 9.99 178 79.36 ± 10.91 > 0.05
PP. mmHg 379 52.73 ± 12.92 201 53.86 ± 13.50 178 51.45 ± 12.15 > 0.05
Heart rate. beats/min 379 69.74 ± 10.25 201 68.62 ± 10.95 178 71 ± 9.26 <0.05
ABI left 379 1.14 ± 0.10 201 1.15 ± 0.10 178 1.12 ± 0.09 > 0.05
ABI right 378 1.13 ± 0.10 201 1.15 ± 0.10 177 1.12 ± 0.09 > 0.05
Average C-IMT. mm 377 0.74 ± 0.10 199 0.75 ± 0.10 178 0.72 ± 0.09 > 0.05
Maximum C-IMT. mm 377 0.90 ± 0.12 199 0.92 ± 0.13 178 0.88 ± 0.11 > 0.05
PWV. m/s 374 8.65 ± 1.60 197 8.71 ± 1.67 177 8.57 ± 1.52 > 0.05
VDP-Cornell. mV/ms 372 1546.71 ± 561.74 201 1467.04 ± 622.79 171 1640.36 ± 464.75 <0.05
Basal glycaemia. mg/dL 379 95.46 ± 27.03 201 97.96 ± 30.51 178 92.64 ± 22.21 <0.05
Plasma creatinine. mg/dL 379 0.86 ± 0.19 201 0.95 ± 0.18 178 0.75 ± 0.14 <0.05
HDL-cholesterol. mg/dL 366 53.58 ± 14.09 196 54.33 ± 14.86 170 52.72 ± 13.14 > 0.05
LDL- cholesterol. mg/dL 373 132.76 ± 34.46 198 130.45 ± 35.53 175 135.37 ± 33.11 > 0.05
Triglycerides. mg/dL 379 128.05 ± 72.20 201 140.52 ± 83.03 178 113.96 ± 54.44 <0.05
HbA1c. % 370 5.92 ± 0.91 196 5.98 ± 0.99 174 5.85 ± 0.79 <0.05
Haemoglobin. g/dL 376 15.08 ± 1.15 200 15.57 ± 1.12 176 14.52 ± 0.89 <0.05
hs-CRP. mg/dL 360 0.31 ± 0.43 194 0.29 ± 0.39 166 0.33 ± 0.48 > 0.05
Fibrinogen. mg/dL 366 357.52 ± 65.32 196 347.59 ± 64.42 170 368.96 ± 64.66 > 0.05
Uric acid. mg/dL 379 5.26 ± 1.30 201 5.72 ± 1.14 178 4.73 ± 1.27 > 0.05
Urinary creatinine. mg/dL 372 104.38 ± 52.79 196 122.41 ± 53.23 176 84.30 ± 44.52 <0.05
Microalbuminuria. mg/dL 371 13.07 ± 66.78 195 21.21 ± 90.93 176 4.05 ± 10.33 <0.05
Leukocytes. *1000/μl 265 6.84 ± 1.77 143 7.15 ± 1.71 122 6.48 ± 1.77 > 0.05
Eosinophils. *1000/μl 265 0.21 ± 0.14 143 0.22 ± 0.15 122 0.19 ± 0.13 > 0.05
Lymphocytes. *1000/μl 265 2.49 ± 0.76 143 2.49 ± 0.76 122 2.41 ± 0.64 <0.05
Neutrophils. *1000/μl 265 3.53 ± 1.12 143 3.75 ± 1.08 122 3.28 ± 1.12 > 0.05
Left artery. μm 211 108.35 ± 13.61 112 106.85 ± 13.33 99 110.05 ± 13.77 > 0.05
Right artery. μm 212 108.93 ± 12.47 116 109.86 ± 12.02 96 107.81 ± 12.20 > 0.05
Average artery. μm 238 109.11 ± 12.07 129 108.90 ± 12.00 109 109.36 ± 12.20 > 0.05
Minor artery. μm 238 104.75 ± 12.09 129 104.83 ± 13.03 109 104.66 ± 13.21 > 0.05
Left vein. μm 211 140.93 ± 18.96 112 139.82 ± 18.15 211 140.93 ± 18.96 > 0.05
Right vein. μm 212 142.27 ± 19.15 116 142.99 ± 18.14 212 142.27 ± 19.15 > 0.05
Average vein. μm 238 142.05 ± 18.02 129 141.85 ± 15.94 99 142.18 ± 19.84 > 0.05
Major vein. μm 238 147.33 ± 18.95 129 147.68 ± 16.97 109 146.91 ± 21.12 > 0.05
Left AVIx. μm 176 0.78 ± 0.11 93 0.77 ± 0.11 83 0.79 ± 0.11 > 0.05
Right AVIx. μm 161 0.78 ± 0.11 86 0.78 ± 0.12 75 0.78 ± 0.10 > 0.05
Average AVIx. μm 236 0.78 ± 0.10 127 0.78 ± 0.10 109 0.78 ± 0.09 > 0.05
Table 3. Demographic, physical and basic analytical values of the patients included in the study. ABI: ankle 
brachial index; AVIx: arteriovenous index; BMI: body mass index; C- IMT: carotid intima media thickness; 
DBP: diastolic blood pressure; HbA1c: glycosylated hemoglobin; HDL: high-density lipoprotein; hs-CRP: high 
sensitive C-reactive protein; LDL: low-density lipoprotein; PP: pulse pressure; PWV: pulse wave velocity; SBP: 
systolic blood pressure; SD: standard deviation; VDP: voltage duration product. Artery, vein and AVIx values 
are retinal vessels.
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However, although our research group and others have identified the involvement of TGF-β1 receptors in car-
diovascular and renal damage (as described in the introduction section), to date there are no studies relating the 
presence of gene polymorphic variants in TGF-β1 receptors with cardiovascular damage. The only studies relating 
ALK1 and endoglin polymorphisms with cardiovascular damage show the absence of associations between the 
ALK1 rs2071219 polymorphism and the risks of brain arteriovenous malformations28, and between the endoglin 
rs3739817 polymorphism with human pulmonary arterial HP29. One study with the endoglin rs10987759 poly-
morphism shows a trend toward association with sporadic brain arteriovenous malformations, although it does 
not reach statistical significance30. Conversely, our study shows significant associations between ALK1 rs2071219, 
rs3847859 and endoglin rs3739817 and rs10987759 polymorphisms with several cardiovascular risk factors 
(retinopathy, altered basal glycaemia, heart rate, LDL-cholesterol, hemoglobin levels) in a Spanish population 
with or without HT and DM recruited in a primary care setting.
The association between reduction in the vascular calibre of the retinal vessels and cardiovascular risk is well 
known31. Patients with increased cardiovascular risk have more symptoms of retinopathy, such as dilated retinal 
veins and thinned arterioles. Both signs are associated with increased risk of stroke and coronary heart disease32. 
The thinning of the retinal arteries is related to the increase in pulse wave velocity and in pulse pressure33. TGF-β1 
is involved in the thinning of the capillary basal lamina of the retina through its receptors ALK1 and ALK5 by 
upregulation of profibrotic genes in perycites34. The specific role of ALK1 in the vasculature is complex. In our 
study, being carrier of the A allele in the ALK1 rs2071219 polymorphism is associated with the absence of altered 
basal glycaemia, and the presence of the AA homozygous genotype is associated with a lower presence of retin-
opathy in HT and DM patients. Hyperglycaemia inhibits ALK1 expression, as shown in vitro in endothelial cells, 
SNP Genotype
<average >average P value 
(1) OR (95% CI) (1) P value (2) OR (95% CI) (2)N % N %
Medium Caliber or Retinal Arterioles
rs2071219
GG 20 16.1 25 21.9 Ref. 1.000 Ref. 1.000
AG 71 57.3 46 40.4 0.917 0.961 (0.457-2.024) 0.562 1.607 (0.323-7.993)
AA 33 26.6 43 37.7 0.017 0.486 (0.269-0.877) 0.859 0.906 (0.306-2.686)
rs2071219 dominant
GG 20 16.1 25 21.9 Ref. 1.000 Ref. 1.000
AG + AA 104 83.9 89 78.1 0.180 1.561 (0.814-2.994) 0.486 1.697 (0.384-7.508)
rs2071219 recessive
AA 33 26.6 43 37.7 Ref. 1.000 Ref. 1.000
AG + GG 91 73.4 71 62.3 0.062 1.692 (0.974-2.938) 0.964 0.976 (0.348-2.741)
SNP Genotype
Yes No P value 
(1) OR (95% CI) (1) P value (2) OR (95% CI) (2)N % N %
Presence of Altered Basal Glycaemia
rs2071219
GG 14 31.1 59 17.7 Ref. 1.000 Ref. 1.000
AG 19 42.2 176 52.7 0.105 2.000 (0.864-4.629) 0.692 1.359 (0.298-6.207)
AA 12 26.7 99 29.6 0.747 0.882 (0.410-1.895) 0.518 0.668 (0.197-2.268)
rs2071219 dominant
GG 14 31.1 59 17.7 Ref. 1.000 Ref. 1.000
AG + AA 31 68.9 275 82.3 0.030 2.161 (1.079-4.329) 0.415 1.745 (0.457-6.668)
rs2071219 recessive
AA 12 26.7 99 29.6 Ref. 1.000 Ref. 1.000
AG + GG 33 73.3 235 70.4 0.685 0.865 (0.428-1.746) 0.710 1.242 (0.396-3.889)
Table 4. Distribution of ALK1 rs2071219 genotypes according to the medium caliber of retinal arterioles and to 
the presence of altered basal glycaemia. P value & OR adjusted by sex and age (1) and by sex, age, DM, HTA, DL, 
tobacco, alcohol and BMI (2). CI = confidence interval; OR = odd ratio; ref.=reference; SNP = single nucleotide 
polymorphism. Statistically significant results in bold.
SNP Genotype
<70 bpm >70 bpm P value 
(1) OR (95% CI) (1) P value (2) OR (95% CI) (2)N % N %
rs3847859
GG 77 36.0 43 26.1 Ref. 1.000 Ref. 1.000
AG 115 53.7 88 53.3 0.002 0.362 (0.188-0.698) 0.021 0.272 (0.090-0.824)
AA 22 10.3 34 20.6 0.023 0.495 (0.270-0.908) 0.051 0.366 (0.134-1.005)
rs3847859 dominant
GG 77 36.0 43 26.1 Ref. 1.000 Ref. 1.000
AG + AA 137 64.0 122 73.9 0.042 0.628 (0.401-0.984) 0.200 0.625 (0.305-1.282)
rs3847859 recessive
AA 22 10.3 34 20.6 Ref. 1.000 Ref. 1.000
AG + GG 192 89.7 131 79.4 0.006 2.263 (1.263-4.054) 0.028 3.005 (1.126-8.019)
Table 5. Distribution of ALK1 rs3847859 genotypes according to the basal heart rate. P value & OR adjusted 
by sex and age (1) and by sex, age, DM, HTA, DL, tobacco, alcohol and BMI (2). Bpm: beats per minute; 
CI = confidence interval; OR = odd ratio; ref.=reference; SNP = single nucleotide polymorphism. Statistically 
significant results in bold.
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or in vivo in streptozotocin-induced diabetes mellitus in mice35. ALK1 overexpression affects the migration and 
proliferation of human retinal capillary endothelial cells, thus promoting the remodelling of newly formed blood 
vessels and preventing angiogenesis36. The presence of the AA recessive genotype in the ALK1 rs2071219 poly-
morphism is associated with the absence of hyperglycaemia, and not elevated glucose levels prevents the inhibi-
tion of ALK1 expression, as previously described35. This normoglycaemic scenario with normal levels of ALK1 
expression would result in a lower presence of retinopathy and would favour the migration and proliferation of 
endothelial cells and the remodelling of retinal blood vessels, although an in-depth mechanistic study would be 
needed to corroborate our hypothesis.
Heart rate variability is linked to cardiovascular risk factors such as HT and obesity, and decreased heart 
rate variability increases cardiovascular risk37. Moreover, patients in advanced chronic kidney disease stage have 
reduced heart rate variability38. Resting heart rate predicts cardiovascular diseases and longevity, and it is also 
an important marker of outcome in heart failure and other cardiovascular diseases39. High resting heart rate is 
also associated with increased risk of type 2 diabetes40. In our study, being carrier of the G allele in the ALK1 
rs3847859 polymorphism is associated with a lower basal heart rate, which may be a genetic advantage in the face 






GG 120 68.5 ± 0.9
AG 203 69.7 ± 0.7
AA 56 72.6 ± 1.3
P value (1)
GG vs AG 0.877
GG vs AA 0.035
AG vs AA 0.170
P value (2)
GG vs AG 1.000
GG vs AA 0.143
AG vs AA 0.109
rs3847859 dominant
GG 120 68.5 ± 0.9
AG + AA 259 71.2 ± 0.8
P value (1) 0.026
P value (2) 0.551
rs3847859 recessive
AA 56 72.6 ± 1.3
AG + GG 323 69.1 ± 0.6
P value (1) 0.017






GG 119 129.74 ± 3.11
AG 199 137.02 ± 2.40
AA 55 123.86 ± 4.56
P value (1)
GG vs AG 0.194
GG vs AA 0.863
AG vs AA 0.033
P value (2)
GG vs AG 1.000
GG vs AA 1.000
AG vs AA 1.000
rs3847859 dominant
GG 119 129.76 ± 3.11
AG + AA 254 130.44 ± 2.58
P value (1) 0.861
P value (2) 0.764
rs3847859 recessive
AA 55 123.86 ± 4.56
AG + GG 318 133.38 ± 1.96
P value (1) 0.056
P value (2) 0.522
Table 6. Statistically significant results in the distribution of ALK1 rs3847859 polymorphisms according to 
basal heart rate and plasma LDL cholesterol. P value adjusted by sex and age (1) and by sex, age, DM, HTA, 
DL, tobacco, alcohol and BMI (2). SD: standard deviation; SNP: single nucleotide polymorphism. Statistically 
significant results in bold.
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rs10987759 polymorphism is associated with an increased heart rate, circumstance that may increase the car-
diovascular risk in these HT and DM patients. At this point in time, there is no study in the scientific literature 
describing the role of ALK1 and endoglin receptors in heart rate regulation, so we cannot explain how the pres-
ence of these genetic polymorphisms is associated to changes in heart rate. But our study opens a promising line 
of research that can assign a new role to these endothelial receptors in the regulation of heart rate.
LDL-cholesterol levels, even in those patients with normal values, are related to the presence and extent of sys-
temic atherosclerosis, independently of other cardiovascular risk factors. As LDL-cholesterol levels increase there 
is a proportional increase in the prevalence of atherosclerosis and its thrombotic complications41. Reduction in 
LDL-cholesterol levels is beneficial to the reduction of atherosclerosis-related cardiovascular disease risk42. ALK1 
expression is increased in human coronary atherosclerotic lesions43. In patients with hypercholesterolemia, ALK1 
acts as a low-affinity, high-capacity receptor for LDL-cholesterol in endothelial cells. ALK1 binds LDL-cholesterol 
with lower affinity than the LDL-receptor and saturates only at hypercholesterolemic concentrations, and medi-
ates LDL-cholesterol uptake in endothelial cells through an endocytic pathway that prevents the ligand from 
degradation and promotes LDL-cholesterol transcytosis, contributing to the initiation of atherosclerosis44. On 
the other hand, endoglin modulates ALK-1 ligand binding and signalling. Hypercholesterolemia alters endoglin 
expression and signalling, causing endothelial or vascular dysfunction before the initiation of atherosclerotic 
lesions45. All these findings suggest the participation of the endothelial receptors ALK1 and endoglin in the regu-
lation of atherosclerosis, mainly exerting an antiatherogenic effect. Therefore, the identification of the presence of 
ALK1 rs3847859 and endoglin rs3739817 polymorphisms, which we have observed to be associated with higher 
LDL-cholesterol levels, could be of clinical relevance to identify patients with an increased atherosclerotic risk, 
and therefore, with a higher probability of suffering adverse cardiovascular events.
The relationship between total haemoglobin levels and cardiovascular risk is controversial. Increased haemo-
globin concentration leads to increased blood viscosity, increased peripheral resistance and reduced blood flow 
and perfusion46. The Framingham Heart Study reported the relationship between haematocrit and cardiovascu-
lar disease incidence in women after adjusting for multiple cardiovascular risk factors47. Elevated haemoglobin 
levels are associated with acute myocardial infarction in men48. There is also an association between total hae-
moglobin levels and cardiovascular incidence (ischemic heart disease, stroke) in men49. Gender differences may 
be explained by the different haemoglobin concentration between men and women, whose levels might not be 
high enough to increase cardiovascular risk. However, the association found in our study is gender independent. 
On the other hand, the red blood cells membrane and the released haemoglobin have atherogenic activities, as 
extracellular and oxidized haemoglobin species induce lipid peroxidation and endothelial damage50. However, 
there are no studies directly relating endoglin to haemoglobin levels, although the regulatory role of this receptor 
in the processes of angiogenesis51 seems to suggest that it should have a role, although unknown, that may affect 
the haemoglobin levels in plasma. The fact that we have detected that being carrier of the C allele in the endoglin 
rs10987759 polymorphism is associated with higher haemoglobin levels reinforces this hypothesis.
One of the main limitations of our findings is that this is a retrospective study. Moreover, due to the number 
of analysed patients, the statistical power of the study is limited, so it is possible that some statistically significant 
differences that actually exist have not been detected. When interpreting these results, it should be taken into 
account that in our recruited population of hypertensive and diabetic patients there were not enough patients 





GG 331 132.94 ± 1.87
AG 40 128.68 ± 5.37
AA 2 185.02 ± 24.01
P value (1)
GG vs AG 1.000
GG vs AA 0.094
AG vs AA 0.068
P value (2)
GG vs AG 1.000
GG vs AA 0.246
AG vs AA 0.281
rs3739817 dominant
GG 331 132.93 ± 1.87
AG + AA 42 156.85 ± 12.30
P value (1) 0.055
P value (2) 0.642
rs3739817 recessive
AA 2 185.70 ± 24.01
AG + GG 371 130.81 ± 2.84
P value (1) 0.026
P value (2) 0.081
Table 7. Statistically significant results in the distribution of endoglin rs3739817 polymorphisms according to 
plasma LDL cholesterol. P value adjusted by sex and age (1) and by sex, age, DM, HTA, DL, tobacco, alcohol and 
BMI (2). SNP: single nucleotide polymorphism. Statistically significant results in bold.
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only analysed the other two genotypes, CT and TT. Studies should be done in a larger population in order to 
confirm our results. We have not measured plasma soluble endoglin in all patients, because the phenotypic mod-
ifications caused by these polymorphisms are not detectable by the available antibodies or ELISAs for soluble 
endoglin. On the other hand, in preliminary studies we did not find differences in soluble endoglin plasma levels 
in patients with different polymorphisms of the endoglin gene, although the analysis was not performed in 100% 
of the recruited population. Moreover, it is also possible that these polymorphic variants do not affect the extra-
cellular domain of endoglin (from which the soluble endoglin is released, after the proteolytic cleaving action of 
metalloproteinase MMP-14), but rather the structure of the membrane-bound endoglin.
Summarizing, ours study shows for the first time that the presence of certain ALK1 and endoglin polymorphic 
variants is associated to several cardiovascular risk factors (retinal artery thickness, altered basal glycaemia, heart 
rate, LDL-cholesterol and haemoglobin levels) in a Spanish population and therefore, the presence of these poly-
morphisms may be relevant to increase the risk of cardiovascular events in these patients. Our work reinforces the 
pre-existing knowledge of the influential role of these endothelial TGF-β1 receptors in cardiovascular regulation. 
Our findings suggest that the analysis of these polymorphisms in populations at risk (HT and DM patients), in 
combination with the determination of other parameters and biomarkers, could implement the diagnosis and 






TT 319 15.02 ± 0.06
CT 56 15.34 ± 0.14
CC 1 17.17 ± 1.01
P value (1)
TT vs CT 0.101
TT vs CC 0.104
CT vs CC 0.220
P value (2)
TT vs CT 0.605
TT vs CC 0.058
CT vs CC 0.112
rs10987759 dominant
TT 319 15.02 ± 0.06
CT + CC 57 16.26 ± 0.51
P value (1) 0.017
P value (2) 0.114
rs10987759 recessive
CC 1 17.17 ± 1.01
CT + TT 375 15.18 ± 0.07
P value (1) 0.050






TT 322 69.44 ± 0.56
CT 56 71.12 ± 1.36
CC 1 88.95 ± 10.14
P value (1)
TT vs CT 0.768
TT vs CC 0.167
CT vs CC 0.247
P value (2)
TT vs CT 1.000
TT vs CC 0.219
CT vs CC 0.297
rs10987759 dominant
TT 322 69.44 ± 0.56
CT + CC 57 80.03 ± 5.11
P value (1) 0.040
P value (2) 0.357
rs10987759 recessive
CC 1 88.95± 10.14
CT + TT 378 70.28 ± 0.73
P value (1) 0.067
P value (2) 0.077
Table 8. Statistically significant results in the distribution of endoglin rs10987759 polymorphisms according 
to hemoglobin levels and heart rate. P value adjusted by sex and age (1) and by sex, age, DM, HTA, DL, tobacco, 
alcohol and BMI (2). SNP: single nucleotide polymorphism. Statistically significant results in bold.
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Methods
This cross-sectional study was performed in 379 subjects aged 20-80 years with or without HT and DM. They 
were recruited in the Primary Care Research Unit of La Alamedilla Health Centre, Salamanca (Spain), covering a 
population of 46,000 inhabitants. We considered HT patients when the mean of three different BP measurements 
was ≥140 mm Hg for systolic blood pressure (SBP) or ≥ 90 mm Hg for diastolic blood pressure (DBP) or when 
patients received antihypertensive treatment. DM was diagnosed when basal plasma glucose ≥126 mg/dL, glyco-
sylated hemoglobin (HbA1c) > 6,5% or when patients received antidiabetic treatment. Obesity was diagnosed by 
body mass index (BMI) ≥ 30 kg/m2. Dyslipidemia was diagnosed when total cholesterol >4.9 mmol/L (190 mg/
dL) or low density lipoprotein cholesterol >3 mmol/L (115 mg/dL) or high-density lipoprotein cholesterol: 
men <1.0 mmol/L (40 mg/dL), women <1.2 mmol/L (46 mg/dL) or triglycerides >1.7 mmol/L (150 mg/dL)52. 
Exclusion criteria: patients recruited in a clinical trial or with serious comorbidities, and patients unable to follow 
the protocol requirement (psychological and/or cognitive disorders, failure to cooperate, educational limitations 
and problems in understanding written language, and failure to sign the informed consent document). Controls 
subjects (75 subjects, 51 men (68%), 24 women (32%)) were normotensive and normoglycaemic patients without 
detectable renal and cardiovascular alterations. We also evaluated previous history of cardiovascular disease, 
heart failure and cerebrovascular disease.
Ethical and legal issues. The experimental protocol was in accordance with the Declaration of Helsinki 
(2008) of the World Medical Association, approved by the Institute of Biomedical Research of Salamanca 
(IBSAL) Ethics Committee and complied with Spanish data protection law (LO 15/1999) and specifications (RD 
1720/2007). All participants recruited in the study signed an informed consent.
Anthropometric measurements. We calculated BMI (kg/m2) measuring height with a portable system 
(Seca 222, Hamburg, Germany) and body weight using a homologated electronic scale (Seca 70; precision ± 
0.1 kg).
Plasma and urine determinations. We measured basal glucose, HbA1c, high-density lipoprotein 
(HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, triglycerides, creatinine in plasma, and microal-
bumin and creatinine in urine in samples collected in the morning, as we previously described7,17,53,54, after fasting 
for at least 8 hours, using standard automatic techniques on a blind basis in the Biochemistry laboratory of the 
University Clinical Hospital, Salamanca (Spain).
Blood pressure determination. We evaluate office BP after three measurements of SBP and DBP with a 
validated OMRON model M7 sphygmomanometer (Omron Health Care, Kyoto, Japan) following the recommen-
dations of the European Society of Hypertension (ESH)52. We calculated SBP, DBP, and pulse pressure with the 
mean values of the second and third measurements.
Evaluation of peripheral arterial disease. We analyzed the ankle–brachial index (ABI) at 22–24 °C in 
patients refrained from drinking coffee or smoking tobacco for at least 8 h before measurements. With patients 
lying in supine position resting for 20 min and with feet uncovered, we measured BP in the lower limbs with a 
portable Doppler system Minidop Es-100Vx (Hadeco Inc, Miyamae-ku Kawasaki, Japan). We calculated ABI for 
each foot by dividing the higher of the two SBP in the ankle by the higher of the two SBP in the arm. An ankle–
brachial index <0.9 is considered pathological52.
Determination of left ventricular hypertrophy. We performed electrocardiography (ECG) with a 
General Electric MAC 3.500 ECG System (Niskayuna, New York, USA) that measures wave voltage and dura-
tion and estimates Cornell voltage duration product (VDP)55. Left ventricular hypertrophy was defined as a 
Sokolow-Lyon index >3.5 mV; RaVL >1.1 mV, Cornell VDP > 244 mV*ms or RaVL >1.1 mV52.
Determination of pulse wave velocity. We evaluated pulse wave velocity (PWV) with the SphygmoCor 
System (AtCor Medical Pty Ltd, Head Office, West Ryde, Australia) in the carotid and femoral arteries with 
patients in supine position measuring the delay with respect to the ECG wave. We obtained distance measure-
ments with a measuring tape from the sternal notch to the carotid and femoral arteries at the sensor location.
Assessment of carotid intima-media thickness. In order to optimize reproducibility, we obtained auto-
mated measurements of carotid intima-media thickness (IMT) with a Micromax ultrasound device (SonoSite Inc, 
Bothell, WA) paired with a 5–10 MHz multifrequency high-resolution linear transducer with Sonocal software. 
We made measurements of the common carotid in a 10 mm longitudinal section at 1 cm from the bifurcation 
in the proximal wall, and in the distal wall in the lateral, anterior and posterior projections, following an axis 
perpendicular to the artery in order to discriminate two lines: one for the intima-blood interface and the other 
for the media-adventitious interface. We obtained average values (average carotid IMT) and maximum values 
(maximum carotid IMT) automatically calculated by the software from six measurements of both the right and 
left carotid arteries)56. We considered abnormal average IMT if >0.90 mm or in the presence of atherosclerotic 
plaques with a diameter of 1.5 mm or a focal increase of 0.5 mm or 50% of the adjacent IMT52.
Evaluation of renal function. We estimated glomerular filtration rate using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation57, the Modification of Diet in Renal Disease- Isotopic Dilution 
Mass Spectrometry (MDRD-IDMS)58 and proteinuria (albumin/creatinine ratio) following the criteria of 
the 2013 European Society of Hypertension/European Society of Cardiology Guidelines52. Subclinical renal 
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damage is present when glomerular filtration rate is below 30–60 mL/min/1.73 m2 or microalbuminuria between 
30–300 mg/24 h or albumin–creatinine ratio between 30–300 mg/g, 3.4–34 mg/mmol. We considered renal dis-
ease as a glomerular filtration rate <30 mL/min/1.73 m2, proteinuria > 300 mg/24 h or albumin/creatinine ratio> 
300 mg/24 h52.
Evaluation of retinopathy. We obtained nasal and temporal images centered on the disk using a Topcon 
TRC NW 200 non-mydriatic retinal camera (Topcon Europe B.C., Capelle a/d Ijssel, The Netherlands), as we 
previously described17,54,59,60. We loaded images into our own developed software, AV Index calculator (Registry 
no. 00/2011/589), which automatically estimates the mean caliber of veins and arteries as an arteriole-venule 
ratio, arteriovenous index (AVIx). An AVIx of 1.0 suggests that arteriolar and venular diameters in that eye are 
on average the same, whereas a smaller AVR suggests narrower arterioles. We used the pairs of main vessels in 
the upper and lower temporal quadrants, and we rejected all other vessels, in order to improve reliability and 
efficiency of the process, analyzing measures for each quadrant separately and together to estimate the mean 
measure in each eye.
Cardiovascular risk assessment. We estimated morbidity and mortality cardiovascular risk (CVR) using 
the 2013 guidelines of the ESH52, based on cardiovascular risk factors, BP, asymptomatic organ damage and pres-
ence of diabetes, symptomatic cardiovascular disease or chronic kidney disease.
DNA isolation and genotyping. We obtained genomic DNA from peripheral blood leukocytes by the 
phenol-chloroform method61. We identified ALK1 rs3847859 and rs2071219 and endoglin rs73739817 and 
rs10987759 polymorphisms using the allelic discrimination assay with TaqMan probes (Life Technologies, 
Carlsbad, California, USA) (Table 1), specific oligonucleotides to amplify the regions containing the poly-
morphisms and two labelled probes with the fluorochromes VIC and FAM to detect both alleles of each poly-
morphism62. We carried out the reaction with the Universal PCR Master Mix in the Real-Time PCR system of 
Step-One Plus (Applied Biosystems, Forster, CA, USA). A 5% of random samples were re-genotyped in order to 
ensure the reproducibility.
Statistical analysis. We used the SPSS v.21.0 software (Armonk, New York, USA) as we previously 
described63. We used the chi-squared test for each polymorphism in order to test the conformity to the 
Hardy-Weinberg equilibrium in control group subjects. We analysed associations between the different clinical 
and molecular qualitative variables by cross tabs and the Pearson X2 test. We calculated the odds ratio (OR) and 
95% confidence intervals with a logistic regression model to evaluate the association with the risk to develop 
the disease. We applied the ANOVA test to compare quantitative variables and the influence of polymorphism 
distribution in those cases that followed a parametric distribution (Levene’s test for homogeneity of variances, 
p > 0.05). We used the Mann Whitney U test when data followed a non-parametric distribution. We performed 
a statistical adjustment by sex and the continuous variable of age, and an additional statistical adjustment by HT, 
diabetes, dyslipidemia, abdominal obesity, tobacco and alcohol consumption, in order to consider confounding 
variables. The statistical power of the main hypothesis tests, accepting an alpha risk of 0.05 in a bilateral contrast 
with our sample of 379 subjects, is as follows: In the case of the rs2071219 dominant genotype and medium 
caliber of retinal arterioles, the statistical power to detect the difference between the mean of the first group 
(111.5 µm) and that of the second (108.5 µm) is 33%. In the case of the rs2071219 dominant genotype and altered 
basal glycemia, the statistical power to detect the difference between 19% of the first group and 10% of the second 
group is 57%, and in the case of the rs3847859 dominant genotype and the heart rate >70 bpm, the statistical 
power to detect the difference between 36% of the first group and 47% of the second is 55%. We considered sta-
tistically significant differences when P-value was <0.05. The statistical analysis of all correlations between the 
polymorphisms and the analysed variables that did not show statistically significant differences are shown in the 
supplementary tables.
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